Pharmaceuticals News and Research

RSS

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

3M Drug Delivery Systems recently advanced its participation in the Asian market with a sponsorship of the Asia Pharma R&D Leaders 2010 event, held March 4 and 5 in Shanghai, China.

16 Apr 2010

First meeting of WHO H1N1 response probe concludes

The first meeting of external experts tasked with reviewing the WHO's handling of the H1N1 (swine flu) virus came to a close Wednesday, with health leaders maintaining it was still too early to declare the pandemic over, Agence France-Presse reports.

16 Apr 2010

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Takeda Pharmaceutical offers milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced it has received a $1 million milestone payment from Takeda Pharmaceutical Company Limited for achieving a pre-established preclinical milestone under the companies' 2006 collaboration agreement, which also calls for additional future milestone payments and royalties on product sales.

16 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

15 Apr 2010

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

15 Apr 2010

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.

15 Apr 2010

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.

15 Apr 2010

New computer simulation technique could speed up drug discovery process

Scientists here are taking the trial and error out of drug design by using powerful computers to identify molecular structures that have the highest potential to serve as the basis for new medications.

15 Apr 2010

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.

15 Apr 2010

Investment report on MIPI

StockPreacher.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Apr 2010

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Achillion Pharmaceuticals, Inc. today presented data from the Company's ongoing Phase 1 clinical trial of ACH-1625 to treat hepatitis C at the European Association for the Study of the Liver's International Liver Congress taking place at the Reed Messe Wien Congress Center in Vienna, Austria from April 14-18, 2010.

15 Apr 2010

Mylan announces quarterly dividend to preferred stock holders

Mylan Inc. today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on May 17, 2010, to holders of preferred stock of record as of May 1, 2010.

15 Apr 2010

Phase Forward's European Users Conference to be held in Budapest, Hungary

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual European Users Conference (EUC) April 21 - 22 at the Corinthia Hotel in Budapest, Hungary.

15 Apr 2010

People with disabilities may be unable to afford Medicare Advantage plan under healthcare provisions

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 are the most powerful developments in decades affecting healthcare coverage for people with disabilities, according to Allsup, a nationwide provider of Social Security disability representation and Medicare plan selection services.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

CHPPR survey: 58% of Americans support repealing health care reform legislation

Fifty-eight percent of Americans (96 percent of Republicans, 10 percent of Democrats and 54 percent of Independents) support repealing the health care reform legislation that was signed into law by President Barack Obama in March, according to a new national survey conducted April 6 - 10 by researchers from Indiana University's Center for Health Policy and Professionalism Research.

15 Apr 2010

Pharmaceuticals News and Research

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

First meeting of WHO H1N1 response probe concludes

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Takeda Pharmaceutical offers milestone payment to XOMA

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

New computer simulation technique could speed up drug discovery process

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Investment report on MIPI

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Mylan announces quarterly dividend to preferred stock holders

Phase Forward's European Users Conference to be held in Budapest, Hungary

People with disabilities may be unable to afford Medicare Advantage plan under healthcare provisions

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

CHPPR survey: 58% of Americans support repealing health care reform legislation

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence